Cartesian Therapeutics has announced positive topline results from its Phase IIb clinical trial evaluating Descartes-08, an autologous, mRNA-engineered chimeric antigen receptor T-cell therapy ...

Cartesian Therapeutics updates on Descartes ... Recent Pipeline Progress and Anticipated Milestones Announced Positive Updated Long-Term Results from Phase 2b Trial of Descartes-08 in Participants ...

Updated Phase 2a Open-Label Trial Results Cartesian today also announced positive updated results ... s recurring losses from operations and negative cash flows, substantial fluctuation in the ...

Cartesian Therapeutics, Inc. (NASDAQ: RNAC), (“the Company”) a clinical-stage biotechnology company pioneering mRNA cell therapies for autoimmune diseases, today announced positive twelve ...

Gil Blum’s rating is based on several encouraging developments regarding Cartesian Therapeutics’ Descartes-08 treatment for severe AChR positive myasthenia gravis. The FDA’s acceptance of ...

Analysts do not expect the company to be profitable this year, which aligns with the reported negative basic and diluted EPS (Earnings Per Share) of -55.74 USD and -55.78 USD, respectively. On a more ...

Updated Phase 2a Open-Label Trial Results Cartesian today also announced positive updated results ... s recurring losses from operations and negative cash flows, substantial fluctuation in the ...